FDA Approves Cobenfy for Adults With Schizophrenia

THURSDAY, Nov. 14, 2024-- The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in adults.The oral medication represents the first new...